Company: DMAAR
Filing Date: 2025-05-20
Form Type: 10-Q
Source: 0001213900-25-046061
Chunk: 1

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-05-20
Form: 10-Q
Item: Part I, Item 1
Chunk 1
---
 31, 2025 and December 31, 2024, respectively 
     1,052  
     986 
  
    Share subscription receivable 
     (852,379) 
     — 
  
    Additional paid-in capital 
     —  
     34,014 
  
    Accumulated deficit 
     (6,325,023) 
     (279,845)
  
    Total Shareholders’ Deficit 
     (7,176,350) 
     (244,845)
  
    TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT 
    $232,806,487  
    $550,824 

The accompanying notes are an integral part of
the unaudited financial statements.

1

DRUGS MADE IN AMERICA ACQUISITION CORP.

STATEMENT OF OPERATIONS

FOR THE THREE MONTHS ENDED MARCH 31, 2025

(UNAUDITED) 

    General and administrative costs 
    $330,925 
  
    Loss from operations 
     (330,925)

    Other income: 

    Interest earned on cash and investments held in Trust Account 
     1,585,468 

    Net income 
    $1,254,543 

    Weighted average redeemable ordinary shares outstanding – basic and diluted 
     15,177,778 

    Basic and diluted net income per redeemable ordinary share 
    $0.05 

    Weighted average non-redeemable ordinary shares outstanding 
     9,612,762 

    Basic net income per non-redeemable ordinary share 
    $0.05 

    Weighted average non-redeemable ordinary shares outstanding 
     10,330,476 

    Diluted net income per non-redeemable ordinary share 
    $0.05 

The accompanying notes are an integral part of
the unaudited financial statements.

2

DRUGS MADE IN AMERICA ACQUISITION CORP.

STATEMENT OF CHANGES IN SHAREHOLDERS’
DEFICIT

FOR THE THREE MONTHS ENDED MARCH 31, 2025

(UNAUDITED)

    Ordinary Shares

    Share Subscription

    Additional Paid-in

    Accumulated

    Total Shareholders’

    Shares

    Amount

    Receivable

    Capital

    Deficit

    Deficit